Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib followed by pegylated interferon for newly diagnosed chronic-phase chronic myeloid leukemia
ACTRN12612000851864Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Apr 2014
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib and peginterferon alfa-2b in chronic myelogenous leukemia (CML), sponsored by Australasian Leukaemia & Lymphoma Group. Started Apr 2014; status: completed.
02
Drugs
nilotinibpeginterferon alfa-2b
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ACTRN12612000851864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000851864.